Drug Instrument Maker Sector Tumbles

Would this mean they'd rather reinvest the cash into U.S. businesses rather than buy capital goods for subsidiaries and (research and development) overseas?," Lehman analyst Tony Butler said in a note to clients. "Nobody knows, but if this scenario were to come to fruition, it would be negative" for the entire sector. Merrill Lynch also downgraded the company (Waters) to neutral, but analyst Darryl Pardi said he believes the woes are unique to Waters, based on talks with peer suppliers and macro indicators

Drug Instrument Maker Sector Tumbles

BioBOOM Op/Ed: ouCH! Is this just Waters? Or maybe time to short the whole sector. Of course could be a crap year in research with cuts in the NIH budget, and pharma, their customers, in retreat due to regulatory and drug reactions. So budget money goes to lawyers and PR we guess. Also seems many have been announcing some kind of jump into diagnostics or diagnostic OEM type models the last 2 years so something has been going on with the research instrument and reagent tool market to warrant those diversification moves. Will be watching others that suppliers like Millipore, Invitrogen and and Qiagen to see if the trend spreads outside the so called instrument guys. ABI is not having a good run these past few years, that's for sure. Guess they are praying for the proposed cancer genome project too.

2 comments:

job opportunitya said...

Cool blog. I dig your site outline and I plan on
returning again! I just love finding blogs like this
when I have the time.
Please take a journey to my plastic surgery photo blog.

job opportunitya said...

Astonshing blog. I relished in the site and you
know I will be going to it again! Surfing the internet
hepls me to find blogs that arfe just as good.
Go and find my plastic surgery blog.

Blog Archive